Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in healthcare sales in the third quarter, and a rise in its full-year ...
Mavenclad hasn’t really got going yet in sales terms, bringing in a modest €90 million in 2018 from the 50 or so countries it has been approved in to date, albeit up from just €5 million in ...
US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback